Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-08-15 4:19 pm Purchase |
2024-08-06 | 13G | Tenax Therapeutics, Inc. TENX |
Stonepine Capital Management, LLC | 372,797 9.990% |
372,797 (New Position) |
Filing History |
| 2024-07-29 4:04 pm Purchase |
2024-07-24 | 13G | Verastem, Inc. VSTM |
Stonepine Capital Management, LLC | 2,666,666 6.700% |
2,666,666 (New Position) |
Filing History |
| 2024-04-19 4:34 pm Purchase |
2024-04-01 | 13G | Surrozen, Inc. SRZN |
Stonepine Capital Management, LLC | 199,158 6.000% |
199,158 (New Position) |
Filing History |
| 2024-02-14 10:01 am Sale |
2023-12-31 | 13G | UroGen Pharma Ltd. URGN |
Stonepine Capital Management, LLC | 0 0.000% |
-1,304,947 (Position Closed) |
Filing History |
| 2024-02-13 4:35 pm Sale |
2023-12-31 | 13G | Exagen Inc. XGN |
Stonepine Capital Management, LLC | 669,684 3.900% |
-184,358 (-21.59%) |
Filing History |
| 2024-02-13 4:34 pm Sale |
2023-12-31 | 13G | Xeris Biopharma Holdings, Inc. XERS |
Stonepine Capital Management, LLC | 5,937,000 4.300% |
-5,258,189 (-46.97%) |
Filing History |
| 2024-02-13 4:33 pm Sale |
2023-12-31 | 13G | Third Harmonic Bio, Inc. THRD |
Stonepine Capital Management, LLC | 0 0.000% |
-2,152,968 (Position Closed) |
Filing History |
| 2024-02-13 4:32 pm Sale |
2023-12-31 | 13G | SCYNEXIS, Inc. SCYX |
Stonepine Capital Management, LLC | 1,355,186 3.600% |
-1,422,691 (-51.22%) |
Filing History |
| 2024-02-13 4:31 pm Sale |
2023-12-31 | 13G | Rezolute, Inc. RZLT |
Stonepine Capital Management, LLC | 2,768,656 7.000% |
-252,848 (-8.37%) |
Filing History |
| 2024-02-13 4:30 pm Sale |
2023-12-31 | 13G | aTyr Pharma, Inc. ATYR |
Stonepine Capital Management, LLC | 482,258 0.800% |
-4,087,175 (-89.45%) |
Filing History |
| 2024-02-13 4:29 pm Sale |
2023-12-31 | 13G | IO Biotech, Inc. IOBT |
Stonepine Capital Management, LLC | 3,641,345 5.400% |
-309,271 (-7.83%) |
Filing History |
| 2024-02-13 4:28 pm Sale |
2023-12-31 | 13G | GAMIDA CELL LTD GMDAQ |
Stonepine Capital Management, LLC | 3,000,000 2.200% |
-6,854,158 (-69.56%) |
Filing History |
| 2024-02-13 4:27 pm Purchase |
2023-12-31 | 13G | Evolus, Inc. EOLS |
Stonepine Capital Management, LLC | 5,333,004 9.300% |
1,145,557 (+27.36%) |
Filing History |
| 2024-02-13 4:26 pm Sale |
2023-12-31 | 13G | Delcath Systems, Inc. DCTH |
Stonepine Capital Management, LLC | 208,333 0.900% |
-767,675 (-78.65%) |
Filing History |
| 2024-02-13 4:25 pm Purchase |
2023-12-31 | 13G | Aytu BioPharma, Inc. AYTU |
Stonepine Capital Management, LLC | 565,484 9.990% |
1,642 (+0.29%) |
Filing History |
| 2024-02-13 4:24 pm Sale |
2023-12-31 | 13G | Alimera Sciences, Inc. ALIM |
Stonepine Capital Management, LLC | 5,373,732 9.990% |
-3,979 (-0.07%) |
Filing History |
| 2024-02-09 4:16 pm Purchase |
2024-01-31 | 13G | Kiora Pharmaceuticals, Inc. KPRX |
Stonepine Capital Management, LLC | 267,673 9.990% |
267,673 (New Position) |
Filing History |
| 2024-01-31 4:27 pm Purchase |
2024-01-22 | 13G | CalciMedica, Inc. CALC |
Stonepine Capital Management, LLC | 1,045,204 9.700% |
1,045,204 (New Position) |
Filing History |
| 2023-08-24 11:53 am Purchase |
2023-08-15 | 13G | GAMIDA CELL LTD GMDAQ |
Stonepine Capital Management, LLC | 9,854,158 7.900% |
9,854,158 (New Position) |
Filing History |
| 2023-08-16 4:15 pm Purchase |
2023-08-07 | 13G | IO Biotech, Inc. IOBT |
Stonepine Capital Management, LLC | 3,950,616 5.800% |
3,950,616 (New Position) |
Filing History |